| 其它 |
Li, S., Liu, Z., Liu, Y., Li, K., Cong, L., Cao, F., Liu, A., Liu, H., Li, L., Qu, L., Zhai, Y., Wang, F., Zhou, D., Yi, Q., Wang, P., Li, J., Shi, D., Chu, J., Zhang, D., Xu, Q., … Liu, L. (2026). First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2600277. Advance online publication. https://doi.org/10.1200/JCO-26-00277 |
First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial 
PDF的下载单位、IP信息已删除
(2025-6-4)
秋风
Kao
GingerF
Nole
Ali
水煮电吹风
cdercder
Criminology34
愤怒的易文
无极微光
罗Eason
OK
null
DW
YifanWang
v0id
渡人舟
唠叨的大门
anugraphics
七听
皖公网安备34019202002308
